Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening

Fig. 2

Simplified depiction of model. Clinical pathways for strategies 4, 6 and 8 are the same as for strategies 3, 5 and 7, respectively, except that patients identified as low risk are screened biennially instead of no screening. Clinical pathways for progression to in situ or invasive cancer and to death follow the pathways described in Schousboe et al, 2011 [14]). Beyond age 50, in all strategies except strategies 1 and 2, women without family history undergo biennial screening; those with family history undergo annual screening

Back to article page